OBD to present at China BIO Conference

RNS Number : 2513Y

Oxford BioDynamics PLC

08 May 2019

 

8 May 2019

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Oxford BioDynamics to present at China BIO Conference

Oxford BioDynamics Plc, a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that it has been selected to present at the China BIO Partnering Forum in Shanghai on 8 May 2019 with a talk by the Company's Chief Scientific Officer, Dr Alexandre Akoulitchev, entitled "EpiSwitch™ Biomarkers: Practical Applications For Predictive, Prognostic And Diagnostic Patient Stratifications".

The presentation will focus on validated EpiSwitch™ biomarker applications which have demonstrated high efficacy in predictive, prognostic and diagnostic patient stratifications for lung, haematological, prostate, thyroid and skin cancers. Baseline predictive stratifications by EpiSwitch™ for response to immune-checkpoint inhibitors are excellent surrogates for standard primary endpoints used in clinical trials, such as progression free survival. The company has recently entered into its fifth collaboration agreement for the development of predictive biomarkers for immuno-oncology therapeutics with leading pharmaceutical companies. 

Alexandre Akoulitchev, Chief Scientific Officer, Oxford BioDynamics said:

"We are looking forward to establishing new partnerships for OBD's EpiSwitch™ technology in China. Our experience includes working with American and European biopharmaceutical partners to enable precision medicine initiatives through the incorporation of our proprietary, epigenetic-based biomarker platform across the research and development value chain.  Recent milestones include the co-development of a response biomarker to checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC), a disease subtyping biomarker in diffuse B-cell lymphoma (DLBCL), a response biomarker to first line therapy in rheumatoid arthritis (RA), a disease progression biomarker in amyotrophic lateral sclerosis (ALS), and diagnostic and prognostic biomarkers for non-alcoholic steatohepatitis (NASH).  Our partnering models are typically structured as milestone-driven, collaborative R&D and licensing deals and have already attracted significant interest from Chinese Biotech."

-ENDS-

For further details please contact:

Oxford BioDynamics Plc Christian Hoyer Millar, CEO Paul Stockdale, CFO	[phone]
FTI Consulting Financial Public Relations Adviser Brett Pollard Natalie Garland-Collins	[phone]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.

About China BIO 2019

ChinaBio® Partnering Forum is the premier life science partnering event in China. The conference will be held May 8-9 in Shanghai, attracting biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.

The organizers expect over 1,400 delegates from more than 500 companies and 25 countries to attend, making it the largest partnering conference in China.

 

END

 

 

NRABDGDUUBGBGCR